Metabolic Syndrome and Obesity Up Risk of Mortality in CRC

This article originally appeared here.
Share this content:
Metabolic Syndrome and Obesity Up Risk of Mortality in CRC
Metabolic Syndrome and Obesity Up Risk of Mortality in CRC

TUESDAY, Sept. 13, 2016 (HealthDay News) -- For patients with early-stage colorectal cancer (CRC), the presence of metabolic syndrome (MetSyn) and obesity is associated with increased risk of mortality, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Elizabeth M. Cespedes Feliciano, Sc.D., from Kaiser Permanente Northern California in Oakland, and colleagues studied 2,446 patients with early-stage CRC diagnosed from 2006 to 2011. Participants were classified according to the presence or absence of MetSyn and obesity.

The researchers found that 601 patients died over a median follow-up of six years, 325 as a result of CRC. For overall survival the hazard ratios were 1.45 for obese patients with MetSyn (95 percent confidence interval [CI], 1.12 to 1.82); 1.09 for non-obese with MetSyn (95 percent CI, 0.83 to 1.44); and 1.00 for obese patients without MetSyn (95 percent CI, 0.80 to 1.26), compared to non-obese patients without MetSyn. CRC-related survival was predicted by obesity with MetSyn (hazard ratio, 1.49; 95 percent CI, 1.09 to 2.02). There was an increase in the risk of death with the number of MetSyn components present, which was independent of obesity.

"Patients with early-stage CRC with obesity and MetSyn have worse survival, overall and CRC related," the authors write.

Two authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Seeks to Increase Number of Generic Drugs on Market

FDA Seeks to Increase Number of Generic Drugs ...

Agency will now give priority reviews to new generic drugs until there are at least three available

PPIs Not Found to Raise Risk of Alzheimer's Disease

PPIs Not Found to Raise Risk of Alzheimer's ...

New research debunks other studies suggesting that PPIs cause mental decline

Aspirin Effective in Pregnancies at High Risk for Preeclampsia

Aspirin Effective in Pregnancies at High Risk for ...

Odds of preeclampsia drop for high-risk women who take 150 mg of aspirin daily, researchers find

is free, fast, and customized just for you!

Already a member?

Sign In Now »